Structure

InChI Key LTINZAODLRIQIX-FBXRGJNPSA-N
Smile COCC1=C(C(=O)OC(C)OC(=O)OC(C)C)N2C(=O)[C@@H](NC(=O)/C(=N\OC)c3csc(N)n3)[C@H]2SC1
InChI
InChI=1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H27N5O9S2
Molecular Weight 557.61
AlogP 0.83
Hydrogen Bond Acceptor 14.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 10.0
Polar Surface Area 180.97
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 37.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial penicillin-binding protein inhibitor PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 81700 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Osteomyelitis 0 D010019 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
12.08
Skin and subcutaneous tissue disorders
11.62
Gastrointestinal disorders
9.42
Nervous system disorders
8.12
Immune system disorders
7.53
Investigations
7.47
Respiratory, thoracic and mediastinal disorders
5.0
Renal and urinary disorders
4.81
Psychiatric disorders
4.22
Infections and infestations
4.09
Musculoskeletal and connective tissue disorders
3.64
Vascular disorders
3.51
Cardiac disorders
3.31
Injury, poisoning and procedural complications
3.31
Metabolism and nutrition disorders
3.12
Hepatobiliary disorders
2.99
Blood and lymphatic system disorders
2.6

Cross References

Resources Reference
ChEBI 3505
ChEMBL CHEMBL1201016
DrugCentral 555
EPA CompTox DTXSID1022766
FDA SRS 2TB00A1Z7N
KEGG C08115
PubChem 6526396
SureChEMBL SCHEMBL27071